Table 1.
Examples of ongoing clinical trials with IL-7 and IL-7R in cancer immunotherapy.
| Drug | Interventions | Conditions | Status | Phases | NCT No. |
|---|---|---|---|---|---|
| IL-7 | IL-7 | Bladder Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Recruiting | I | NCT04054752 |
| IL-7 | Atezolizumab + Glycosylated Recombinant hIL-7 | Bladder Urothelial Carcinoma | Recruiting | II | NCT03513952 |
| NT-I7 | NT-I7 | Recurrent Squamous Cell Carcinoma of Head and Neck | Recruiting | I | NCT04588038 |
| NT-I7 | NT-I7 | AIDS-Related Kaposi Sarcoma | Recruiting | I | NCT04893018 |
| NT-I7 | NT-I7 + Pembrolizumab | Any Advanced Solid Tumors | Recruiting | I/II | NCT04332653 |
| NT-I7 | NT-I7 + Pembrolizumab | Recurrent glioblastoma | Not yet recruiting | II | NCT05465954 |
| NT-I7 | NT-I7 + atezolizumab | Non-Small-Cell Lung | Recruiting | II | NCT04984811 |
| NT-I7 | NT-I7 + Nivolumab | Gastric or Gastro-esophageal Junction or Esophageal Adenocarcinoma | Recruiting | II | NCT04594811 |
| NT-I7 | NT-I7 + Placebo | Malignant Glioma | Active, not recruiting | I | NCT02659800 |
| NT-I7 | NT-I7 + Placebo + Temozolomide + Radiation therapy | Newly diagnosed GBM | Recruiting | I/II | NCT03687957 |
| NT-I7 | NT-I7 + Kymriah® | Relapsed/Refractory Large B-cell Lymphoma | Recruiting | I | NCT05075603 |
| NT-I7 | NT-I7 + atezolizumab | High-Risk Skin Cancers | Recruiting | I/II | NCT03901573 |
| IL-7 expressing CAR-T cells | CAR-T cell (expressing IL7 and CCL19) | Nectin4-positive Advanced Malignant Solid Tumor | Recruiting | I | NCT03932565 |
| IL-7 expressing CAR-T cells | GPC3 and/or TGFβ targeting CAR-T cells (secret IL7/CCL19) | Hepatocellular Carcinoma with GPC3 expression | Recruiting | I | NCT03198546 |
| IL-7 expressing CAR-T cells | CD19-7 × 19 CAR-T plus PD1 monoclonal antibody | Diffuse Large B-cell Lymphoma | Recruiting | I | NCT04381741 |
| C7R-CAR-T | (C7R)-GD2.CART cells+ Cyclophosphamide+ Fludarabine | Diffuse Intrinsic Pontine Glioma High Grade Glioma Embryonal Tumor Ependymal Tumor |
Recruiting | I | NCT04099797 |
| C7R-CAR-T | (C7R)-GD2.CART cells+ Cyclophosphamide+ Fludarabine | Neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance | Recruiting | I | NCT03635632 |